Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel-Reference-Cited by-全球学者库

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

Published:2019-05-01 Issue:5 Volume:5 Page:696
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Wang Zhijie¹,Duan Jianchun¹,Cai Shangli²,Han Miao³,Dong Hua³,Zhao Jun⁴,Zhu Bo⁵,Wang Shuhang⁶,Zhuo Minglei⁴,Sun Jianguo⁵,Wang Qiming⁷,Bai Hua¹,Han Jiefei¹,Tian Yanhua¹,Lu Jing³,Xu Tongfu²,Zhao Xiaochen²,Wang Guoqiang²,Cao Xinkai³,Li Fugen³,Wang Dalei⁸,Chen Yuejun⁸,Bai Yuezong²,Zhao Jing²,Zhao Zhengyi²,Zhang Yuzi²,Xiong Lei²,He Jie¹,Gao Shugeng¹,Wang Jie¹

Affiliation:

1. State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

2. The Medical Department, 3D Medicines Inc, Shanghai, China

3. The Bioinformatics Department, R&D Center of Precision Medicine, 3D Medicines Inc, Shanghai, China

4. Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China

5. Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, China

6. GCP Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

7. Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

8. The 3DMed Clinical Laboratory, 3D Medicines Inc, Shanghai, China

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/5/696/17575157/jamaoncology_wang_2019_oi_180124.pdf

Reference22 articles.

1. Neoantigens in cancer immunotherapy.;Schumacher;Science,2015

2. Targeting neoantigens to augment antitumour immunity.;Yarchoan;Nat Rev Cancer,2017

3. Tumor mutational burden and response rate to PD-1 inhibition.;Yarchoan;N Engl J Med,2017

4. Genetic basis for clinical response to CTLA-4 blockade in melanoma.;Snyder;N Engl J Med,2014

5. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.;Van Allen;Science,2015

Cited by 351 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis;Journal of Translational Medicine;2024-02-04

2. Liquid biopsy in cancer diagnosis, therapy and prognosis;Comprehensive Precision Medicine;2024

3. Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer;The Journal of Applied Laboratory Medicine;2024-01

4. Prospect of immunotherapy alone in patients with advanced NSCLC with high btmb: a review and a meta-analysis;Holistic Integrative Oncology;2023-12-21

5. Circulating Tumor DNA Profiling Approach Based on In Silico Background Elimination Guides Chemotherapy in Nasopharyngeal Carcinoma;Clinical Pharmacology & Therapeutics;2023-12-15